100% of all start ups in the biotechnology business are up on future earnings ,and most aren't even selling product , Cytosorbents is a rare one ,that is selling product overseas while waiting on FDA approval, a very low Market cap, this will change very soon, and everyone will be surprised again and wished they didn't sell and had bought at these levels , institutions will be buying a lot here at these bargain basement prices.